Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Journal of Nanomedicine & Nanotechnology

Abstract

Acquiring to Cancer Stem-Like Cells with Targeted Nano Medicine has Potential for Use in Medicine

Vamshi P*

Multiple drug resistance (MDR) to chemotherapeutic medicines, both inherited and acquired, is a significant barrier to effective cancer treatment. P-glycoprotein and multidrug-resistance-associated proteins are examples of the ATP Binding Cassettes (ABC) transporter super family, which function as extrusion pumps. Blocking the pump proteins physically can tilt the balance between drug input and efflux toward an accumulation of the drug inside the cell, which eventually leads to cell death [1]. This is one of the most effective ways to control the active drug's efflux from the cells. Drugs approved for uses other than treating cancer included MDR modulators, commonly referred to as Chemosensitizers. However, their clinical use is limited by their toxicity, side effects, and low solubility at levels needed to reverse MDR. Prior studies have demonstrated that medications from the selective serotonin reuptake inhibitor (SSRI) family, which are routinely utilised as antidepressants, can function as efficient Chemosensitizers both in vitro and in vivo in tumor-bearing animal models [2]. In this study, we investigated the potential of sertraline (Zoloft®), a member of the SSRI family of drugs, to act as an MDR modulator. Using another FDA-approved medication in combination with sertraline.

Keywords Chemosensitizers; Drug Resistance

Published Date: 2022-12-28; Received Date: 2022-12-03